Background Onalespib is a novel heat shock protein 90 inhibitor (HSP90i). Previous
preclinical and clinical studies with HSP90i have demonstrated activity in EGFR-mutant non …

Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

7073 Background: Erlotinib (TarcevaTM) is an orally available selective EGFR tyrosine-
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …

Purpose A high proportion of patients with wild-type EGFR non-small cell lung cancer
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib
and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …